Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2021 | Novel strategies for treating cytopenia in MDS

Uwe Platzbecker • 27 Jan 2021
ESH MDS 2021
Myelodysplastic Syndromes Imetelstat

Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses novel treatments for cytopenia in myelodysplastic syndromes (MDS) at ESH MDS 2021. In particular, he highlights anti-inflammatory treatments in the early stages of development and a Phase II/III trial (NCT02598661) evaluating imetelstat in patients with low- or intermediate-risk MDS. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

More from Uwe Platzbecker

1:06
Update on the COMMANDS trial: luspatercept is superior to ESA-based therapy in LR-MDS
Uwe Platzbecker • 29 Nov 2023
2:21
MRD clearance in response to HMA + sabatolimab in HR-MDS: insights from STIMULUS-MDS1
Uwe Platzbecker • 29 Nov 2023
1:45
Momelotinib vs SoC in patients with MF and anemia: an analysis from the SIMPLIFY-2 trial
Uwe Platzbecker • 29 Nov 2023
2:51
Analysis of the IMerge trial: the disease-modifying potential of imetelstat in LR-MDS
Uwe Platzbecker • 29 Nov 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals